SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift Laboratories informs about updates

01 Feb 2026 Evaluate
Pursuant to the provisions of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions regarding ‘Format on Statement of Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement (QIP) etc’, Ind-Swift Laboratories has confirmed that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 31st December, 2025 is given in Annexure A.

The above information is a part of company’s filings submitted to BSE.

Ind-Swift Lab. Share Price

144.50 8.55 (6.29%)
05-May-2026 13:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1815.15
Dr. Reddys Lab 1271.65
Cipla 1327.50
Zydus Lifesciences 909.55
Lupin 2347.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×